Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer

Condition:   Head and Neck Carcinoma
Interventions:   Drug: Docetaxel;   Drug: Pembrolizumab
Sponsor:   Medical University of Vienna
Recruiting - verified March 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/1RjaZQP
via IFTTT